UB Paderborn / Katalog / Suche / in CDI

Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study

Journal of thrombosis and haemostasis, 2015-07, Vol.13 (7), p.1245-1253

2015

Link zum Volltext

Verfügbarkeit prüfen

Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2014-06, Vol.39 (11), p.1266-1275

2014

Link zum Volltext

Verfügbarkeit prüfen

Editorial: combination immunosuppressive therapy to treat Crohn’s disease – ready for all age groups? Authors' reply

Alimentary pharmacology & therapeutics, 2019-06, Vol.49 (12), p.1529-1529

2019

Link zum Volltext

Verfügbarkeit prüfen

Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease

Alimentary pharmacology & therapeutics, 2015-10, Vol.42 (7), p.783-792

2015

Link zum Volltext

Verfügbarkeit prüfen

High body mass index is associated with increased risk of treatment failure and surgery in biologic‐treated patients with ulcerative colitis

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (11), p.1472-1479

2018

Link zum Volltext

Verfügbarkeit prüfen

A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (2), p.262-271

2016

Link zum Volltext

Verfügbarkeit prüfen

Systematic review with meta‐analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy

Alimentary pharmacology & therapeutics, 2017-02, Vol.45 (3), p.381-390

2017

Link zum Volltext

Verfügbarkeit prüfen

Magnetic resonance elastography identifies fibrosis in adults with alpha‐1 antitrypsin deficiency liver disease: a prospective study

Alimentary pharmacology & therapeutics, 2016-08, Vol.44 (3), p.287-299

2016

Link zum Volltext

Verfügbarkeit prüfen

Systematic review with meta‐analysis: placebo rates in induction and maintenance trials of Crohn's disease

Alimentary pharmacology & therapeutics, 2017-04, Vol.45 (8), p.1021-1042

2017

Link zum Volltext

Verfügbarkeit prüfen

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Hepatology (Baltimore, Md.), 2017-05, Vol.65 (5), p.1557-1565

2017

Link zum Volltext

Verfügbarkeit prüfen

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

Cell metabolism, 2019-09, Vol.30 (3), p.607-607

2019

Link zum Volltext

Verfügbarkeit prüfen

DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i150-i151

2023

Link zum Volltext

Verfügbarkeit prüfen

P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1308-i1308

2024

Link zum Volltext

Verfügbarkeit prüfen

P820 Targeting MM-SES-CD < 22.5 for endoscopic improvement is feasible in a clinical trial of Crohn’s disease: A post-hoc analysis of SEAVUE

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1526-i1526

2024

Link zum Volltext

Verfügbarkeit prüfen

P409 Optimal endoscopic healing thresholds defined by MM-SES-CD < 22.5 and SES-CD < 4 are associated with low risk of disease progression in Crohn’s disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i847-i848

2024

Link zum Volltext

Verfügbarkeit prüfen

P548 Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S388-S388

2019

Link zum Volltext

Verfügbarkeit prüfen

DOP76 Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i214-i215

2024

Link zum Volltext

Verfügbarkeit prüfen

DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i217-i218

2024

Link zum Volltext

Verfügbarkeit prüfen

P545 Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modelling

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1074-i1075

2024

Link zum Volltext

Verfügbarkeit prüfen

EE406 Economic Impact of Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Induction and Maintenance Phase 3 Results on Work Productivity Loss

Value in health, 2024-06, Vol.27 (6), p.S131-S132

2024

Link zum Volltext

Verfügbarkeit prüfen

PCR158 Assessing the Cost of Work Productivity Loss in a Privately Insured US Population With Inflammatory Bowel Diseases

Value in health, 2024-06, Vol.27 (6), p.S325-S326

2024

Link zum Volltext

Verfügbarkeit prüfen

PRIMARY NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE, DEFINITION, POTENTIAL CAUSES, THERAPEUTIC DRUG MONITORING AND MICROBIOTA – A REVIEW

Applied ecology and environmental research, 2020, Vol.18 (4), p.5505-5525

2020

Link zum Volltext

Verfügbarkeit prüfen

A167 CATEGORIZING ENDOSCOPIC SEVERITY OF CROHN’S DISEASE USING THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD)

Journal of the Canadian Association of Gastroenterology, 2022-02, Vol.5 (Supplement_1), p.45-47

2022

Link zum Volltext

Verfügbarkeit prüfen

P485 Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S354-S355

2019

Link zum Volltext

Verfügbarkeit prüfen

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

Pharmacotherapy, 2015-10, Vol.35 (10), p.979-979

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study

Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease

Editorial: combination immunosuppressive therapy to treat Crohn’s disease – ready for all age groups? Authors' reply

Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease

High body mass index is associated with increased risk of treatment failure and surgery in biologic‐treated patients with ulcerative colitis

A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

Systematic review with meta‐analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy

Magnetic resonance elastography identifies fibrosis in adults with alpha‐1 antitrypsin deficiency liver disease: a prospective study

Systematic review with meta‐analysis: placebo rates in induction and maintenance trials of Crohn's disease

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease

DOP73 Predicting endoscopic improvement in Ulcerative Colitis using the Ulcerative Colitis Severity Index (UCSI)

P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials

P820 Targeting MM-SES-CD < 22.5 for endoscopic improvement is feasible in a clinical trial of Crohn’s disease: A post-hoc analysis of SEAVUE

P409 Optimal endoscopic healing thresholds defined by MM-SES-CD < 22.5 and SES-CD < 4 are associated with low risk of disease progression in Crohn’s disease

P548 Vedolizumab clinical decision support tool predicts hospitalisation, surgery, and healthcare resource utilisation

DOP76 Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies

DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

P545 Long-term efficacy of ozanimod up to 3 years in patient response subgroups identified using group-based trajectory modelling

EE406 Economic Impact of Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Induction and Maintenance Phase 3 Results on Work Productivity Loss

PCR158 Assessing the Cost of Work Productivity Loss in a Privately Insured US Population With Inflammatory Bowel Diseases

PRIMARY NON-RESPONSE IN INFLAMMATORY BOWEL DISEASE, DEFINITION, POTENTIAL CAUSES, THERAPEUTIC DRUG MONITORING AND MICROBIOTA – A REVIEW

A167 CATEGORIZING ENDOSCOPIC SEVERITY OF CROHN’S DISEASE USING THE MODIFIED MULTIPLIER SES-CD (MM-SES-CD)

P485 Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

Suchergebnisse filtern